Prothymosin α and Decapeptide Show No Acute Toxicity in Preliminary Safety Study
Background
Prothymosin α (ProTα) is a naturally occurring protein with known immunomodulatory and anti-cancer properties, while its C-terminal decapeptide, ProTα(100-109), also exhibits significant biological activity. Despite their therapeutic potential, there was a critical absence of comprehensive acute toxicity data for these compounds, hindering further development and clinical translation.
Results
Across all treatment groups, the study observed 0% mortality throughout the 14-day observation period, even at the highest doses of 100 mg/kg for both compounds. Treated mice showed no significant differences in body weight gain compared to the control group (p>0.05), with average weight changes remaining within ±5% of baseline. Furthermore, no overt clinical signs of toxicity, such as changes in behavior, fur condition, or activity levels, were noted in any ProTα or ProTα(100-109)-treated animals. Macroscopic examination of major organs at study termination also revealed no abnormalities. The most critical finding was the complete absence of acute toxicity, indicating a favorable safety profile for both Prothymosin α and ProTα(100-109) at doses up to 100 mg/kg.
Why It Matters
This preliminary safety assessment provides critical foundational data, validating the non-toxic nature of Prothymosin α and ProTα(100-109) at high acute doses. The absence of adverse effects significantly de-risks these compounds, paving the way for more extensive preclinical investigations into their therapeutic efficacy. This positive safety profile is crucial for advancing Prothymosin α and ProTα(100-109) towards potential clinical applications, particularly in areas like immunomodulation or oncology. Future research should focus on sub-acute and chronic toxicity studies, followed by efficacy trials in relevant disease models.